Compugen Ltd. - Ordinary Shares (CGEN)

1.5900Last Price

-0.0100 (-0.63%)Change

Compugen Ltd is a biotechnology company that focuses on the discovery and development of novel drug candidates for immuno-oncology and autoimmune diseases

Utilizing its proprietary algorithmic technology platform, the company identifies new therapeutic targets and generates potential antibody candidates. Compugen is engaged in both internal drug development and collaboration with pharmaceutical partners, aiming to enhance treatment options for patients through innovative therapies that leverage the body's immune system to fight cancer and other conditions.

Compugen Ltd. (NASDAQ: CGEN) is One of Tuesday Morning’s Most Active Stocks

Compugen Ltd. (NASDAQ: CGEN) is one today’s most active stocks by volume. So far today, approximately 61,549 shares of Compugen Ltd. have been exchanged, as compared to an average 30-day volume of 128.42k shares.

Via Investor Brand Network · December 19, 2023

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate.

By Gilead Sciences, Inc. · Via Business Wire · December 19, 2023

Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN

In the past week, there has been a strong surge in interest in biotech stocks and that is a trend that investors ought to look into. Considering the fact that it is a highly innovative sector, it may well be a good move to keep an eye on. There have been certain biotech stocks that have managed to record massive gains in the past week and here is a look at four of those.

Via AB Newswire · June 5, 2023